TrialScientific reports2026

Randomized pilot study of camrelizumab with or without autologous cytokine-induced killer cells in refractory clear cell renal cell carcinoma.

Shuzhan Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.